[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"precision-medicine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:precision-medicine":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,83,113,138,170,195,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642092","precision-obesity-medicine-genetic-prediction-of-response-to-glp-1gip-agonists-100642092",false,"NCT07653412","Precision Obesity Medicine: Genetic Prediction of Response to GLP-1\u002FGIP Agonists.","Prediction of Response to GLP-1\u002FGIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.","Diagenix","Inclusion Criteria:\n\nAge ≥18 years BMI ≥40 kg\u002Fm² or ≥37 kg\u002Fm² with comorbidities Initiation of semaglutide or tirzepatide\n\nExclusion Criteria:\n\nPrior bariatric surgery Secondary causes of obesity Active malignancy Chronic pancreatitis Family history of medullary thyroid carcinoma","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","6 Months","OBSERVATIONAL","Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.\n\nThe aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.",[26,27,28],"Obesity (Disorder)","Anti-obesity Agents","Precision Medicine",[30,31,28,32,33],"Obesity","Genetic Risk Score","GLP-1 Receptor Agonist","GIP\u002FGLP-1 Receptor Agonist","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2026-04-22",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"National and Kapodistrian University of Athens","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":46},"100638562","eating-almonds-before-a-meal-to-control-blood-sugar-100638562","NCT07603739","Eating Almonds Before a Meal to Control Blood Sugar","Interindividual Variability in the Effect of Premeal Almond Supplementation on Glycemic Control - a Double Crossover Study","NUTS","Inclusion Criteria:\n\n* Adults aged 25-50 years\n* Females over 40 years must have had a cycle in the last 6 months\n* Body mass index (BMI) at least 18.5 and at most 55.0 kg\u002Fm2\n* Impaired blood glucose by at least one of the following criteria:\n* Fasting blood glucose at least 100 mg\u002FdL (5.6 mmol\u002FL) and less than 125 mg\u002FdL (6.9 mmol\u002FL)\n* HbA1c at least 5.7% and less than 6.5%\n* Willing and able to comply with study foods\n* Willing and able to ingest acetaminophen as part of study procedures\n* Able to read, speak, and understand English\n\nExclusion Criteria:\n\n* Weight change ≥5% in past 6 months, actively trying to lose weight, or unwilling to remain weight stable throughout the study based on self-report\n* Recent history within past 12 months of medical provider-diagnosed cardiovascular, renal, or liver disease that required treatment\n* Current or past diagnosis of cancer (except skin cancer) in the last 5 years\n* Current or past diagnosis of type 1 or type 2 diabetes\n* Recent history within past 12 months of medical provider-diagnosed gastrointestinal or neurological disorders if not managed\u002Fstable for at least 3 months (with or without treatment)\n* Recent history within past 12 months of medical provider-diagnosed psychiatric disorders including eating disorders or severe depression if not managed\u002Fstable for at least 3 months (with or without treatment)\n* Food allergies or other reasons preventing consumption of study foods\n* Any glucose-lowering medication except biguanides (e.g., Metformin) if stable for at least 3 months or incretins (i.e., GLP-1RA-based) if stable for at least 3 months\n* Current smoking or vaping or history of smoking or vaping in the past 6 months\n* Binge and\u002For heavy drinking (i.e., \\>3 drinks on any given occasion and\u002For \\>7 drinks\u002Fweek)\n* Currently pregnant or planning to become pregnant or breastfeed in the next 3 months by self-report",true,"25 Years","50 Years",{"count":59,"type":21},25,"INTERVENTIONAL",[62],"NA","The goal of this study is to learn whether eating a small serving of almonds before meals can improve blood sugar control in adults who have early signs of problems with blood sugar regulation. The main questions it aims to answer are:\n\n1. Does eating almonds before a meal reduce the rise in blood sugar after eating?\n2. Do some people consistently benefit more than others from eating almonds before meals?",[65,66,28,67],"Glucose Control","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Nutrition",[67,28,69,65,70,71,72],"Precision Nutrition","Impaired Glucose Tolerance","Insulin Resistance","Prediabetes","NOT_YET_RECRUITING","2026-05-16",{"date":76,"type":38},"2026-05-22",{"date":78,"type":21},"2026-06",{"date":80,"type":21},"2028-07",{"name":82,"class":45},"Pennington Biomedical Research Center",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":22,"maxAge":18,"enrollmentInfo":90,"targetDuration":4,"studyType":60,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":46},"100585463","timely-ordering-of-pharmacogenetic-testing-100585463","NCT06902688","Timely Ordering of Pharmacogenetic Testing","Timely Ordering of Pharmacogenetic Testing in Pediatric Oncology","Inclusion Criteria:\n\n* Inpatient at The Hospital for Sick Children\n* Between 6 months to 18 years old\n\nExclusion Criteria:\n\n* Prior pharmacogenetic testing and\u002For prior receipt of a targeted medication\n* Current Intensive Care Unit (ICU) admission\n* Expected hospital discharge is prior to midnight on the day of admission",{"count":91,"type":21},275,[62],"The goal of this trial is to learn if a machine learning (ML) model can help optimize drug therapy in the pediatric population. The main question\\[s\\] it aims to answer are whether a machine learning model predicting receipt of a targeted medication within the next three months:\n\n* Increases the offering of pharmacogenetic testing prior to receipt of a targeted medication\n* Increases the number of patients with pharmacogenetic results prior to receipt of a targeted medication\n* Increases the number of patients who have alteration in medication choice or dose based on pharmacogenetic results\n\nThis trial only focuses on the prediction and provision of participants with a high-risk of receiving a medication with a pharmacogenetic indication in the next three months.",[95,96,97,28],"Machine Learning","Prediction Models","Pediatrics",[99,100,101,102,103],"precision medicine","machine learning","pharmacogenetics","prediction models","pediatrics","2026-03-03",{"date":106,"type":38},"2026-03-05",{"date":108,"type":38},"2025-06-10",{"date":110,"type":21},"2027-06-10",{"name":112,"class":45},"The Hospital for Sick Children",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":55,"sex":17,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":60,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":46},"100559590","the-liver-biobank-lombardia-of-fatty-liver-100559590","NCT06566105","The Liver BIoBank Lombardia of Fatty Liver","The Liver BIoBank Lombardia Genomic Cohort Study (LIVER-BIBLE): Personalized Medicine for the Management of Hepatic and Cardiovascular Thrombotic Complications of Fatty Liver","Inclusion Criteria:\n\n* Blood donors aged between 40 and 65 years presence of clinical diagnosis of overweight or obesity (body mass index-BMI \\> 25 kg\u002Fm2),\n* increased fasting blood glucose or T2D (fasting blood glucose ≥100mg\u002Fdl) or dyslipidemia (triglycerides≥150mg\u002Fdl, HDL\\\u003C45\u002F55 in M\u002FF) or arterial hypertension (n = 2,452, 11.8% of the entire cohort).\n\nExclusion Criteria:\n\n* subjects suffering from chronic degenerative diseases, except hypertension in good compensation and diabetes type 2 mellitus which does not require pharmacological therapy (as is already common practice for eligibility for donation of blood)\n* donors aged \\> 65 and \\\u003C 40 to avoid the introduction of bias","40 Years","60 Years",{"count":123,"type":21},2500,[62],"NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is associated with increased mortality due to multiple causes. HFC has a strong genetic component and the investigators recently showed that it plays a causal role in determining progressive liver disease and insulin resistance.\n\nThe genetic risk score predicting liver fat content (HFC-GRS) improves the stratification of liver related events, and the investigators have preliminary data on new common and rare variants that contribute to NAFLD susceptibility, and on a new non-invasive circulating biomarker associated with hepatic fat and lipotoxicity (Interleukin-32). However, no data are yet available on the causal role of hepatic fat on the procoagulant state associated with NAFLD, which could participate to liver damage and is a causal factor in atherothrombotic complications. The aim of the study is to examine the potential application of a precision medicine approach to the improvement of stratification of the risk of liver-related and cardiovascular thrombotic complications of hepatic fat accumulation (HFC) and non-alcoholic fatty liver disease (NAFLD), with a special focus on the role of procoagulant imbalance in mediating the at-risk phenotypes.",[127,28,128],"NAFLD","Cardiovascular Diseases","2025-11-17",{"date":131,"type":38},"2025-11-18",{"date":133,"type":38},"2020-06-01",{"date":135,"type":21},"2037-12-31",{"name":137,"class":45},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":60,"phases":146,"briefSummary":147,"conditions":148,"keywords":155,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":46},"100609844","evaluating-a-clinical-decision-support-tool-for-antiretroviral-therapy-optimization-100609844","NCT07219862","Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization","Inclusion Criteria:\n\nHIV patients\n\n1. Documented HIV-1 infection\n2. Greater than 18 years of age\n3. Genotype resistance testing previously conducted or scheduled through clinical care\n\nProviders:\n\nHIV care providers who will determine treatment selections, with or without utilizing our clinical decision support tool\n\nExclusion Criteria:\n\nHIV patients:\n\n1\\. Refusal or inability to give informed consent\n\nProviders:\n\n1\\. Refusal to give informed consent",{"count":145,"type":21},250,[62],"This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging.\n\nIn this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care.\n\nThe investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.",[149,150,151,152,153,154,28],"HIV (Human Immunodeficiency Virus)","Clinical Decision Support System (CDSS)","Antiretroviral Therapy, Highly Active","INDIVIDUALIZED THERAPY","AIDS (Acquired Immune Deficiency Syndrome)","Personalized Medicine",[156,157,158,159,160,99],"hiv","clinical decision support system","antiretroviral therapy","aids","personalized medicine","2025-10-20",{"date":163,"type":38},"2025-10-22",{"date":165,"type":21},"2028-09-01",{"date":167,"type":21},"2031-09-01",{"name":169,"class":45},"Keck School of Medicine of USC",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":60,"phases":179,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":46},"100584928","phase-1-study-of-pazopanib-combined-with-palbociclib-for-refractory-solid-tumors-with-co-amplified-in-the-11q13fgf3419ccnd1-100584928","NCT06895733","Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3\u002F4\u002F19\u002FCCND1)","A Multi Cohort Phase IB\u002FII Clinical Study of Pazopanib Combined With Palbociclib for Third Line and Beyond Treatment of Refractory Solid Tumors With Co-amplified in the 11q13(FGF3\u002F4\u002F19\u002FCCND1)","Inclusion Criteria:\n\n1. Voluntarily join this study and sign an informed consent form;\n2. ≥ 18 years old;\n3. Patients with metastatic solid tumors diagnosed by histology or cytology; Queue 1:11q13 co amplified or FGFR1\u002FFGFR2 amplified urothelial carcinoma Queue 2: Head and neck squamous cell carcinoma co amplified in 11q13 region Queue 3:11q13 co amplified other solid tumors\n4. Disease progression or intolerable toxicity confirmed by imaging during or after treatment with at least two standard treatment regimens in the past;\n5. According to RECIST 1.1, there must be at least one measurable lesion;\n6. Can swallow pills normally;\n7. ECOG score: 0-2;\n8. Expected survival period ≥ 12 weeks;\n9. The function of important organs meets the following requirements (no blood components or cell growth factor drugs are allowed to be used within 14 days before the first medication):\n\n   Absolute neutrophil count ≥ 1.5 × 109\u002FL; Platelets ≥ 100 × 109\u002FL; Hemoglobin ≥ 90 g\u002FL; Serum albumin ≥ 30 g\u002FL; Serum total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN, and if there is liver metastasis, ALT and AST ≤ 5ULN; AKP≤ 2.5×ULN；Serum creatinine ≤ 1.5 × ULN; International normalized ratio (INR) ≤ 1.5 (not receiving anticoagulant therapy);\n10. Non surgical sterilization or female patients of childbearing age are required to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill, or condom) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo non-surgical sterilization must have a negative serum or urine HCG test within 7 days prior to their first medication; And it must be during non lactation period; For male patients whose partners are women of childbearing age, effective contraception methods should be used during the trial period and within 3 months after the last administration of the trial drug.\n\nExclusion Criteria:\n\n1. Known history or evidence of interstitial lung disease or active non infectious pneumonia;\n2. Known to have central nervous system metastases;\n3. Within the past 5 years or simultaneously with other malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ);\n4. Suffering from hypertension and unable to achieve good control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); Allow the above parameters to be achieved through the use of antihypertensive therapy; Previously experienced hypertensive crisis or hypertensive encephalopathy;\n5. There are uncontrolled clinical symptoms or diseases of the heart, such as: (1) NYHA grade 2 or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, (5) QTc\\>450ms (male); QTc\\>470ms (female);\n6. For those undergoing thrombolytic or anticoagulant therapy, prophylactic use of low-dose aspirin and low molecular weight heparin is allowed;\n7. Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; If fecal occult blood is positive during the baseline period, a follow-up examination can be conducted. If the result is still positive after the follow-up examination, gastroscopy examination is required;\n8. Tumor invasion of important blood vessels, or the possibility of tumor invasion of important blood vessels in the future research period determined by imaging, may lead to fatal bleeding;\n9. If the patient has pleural effusion, ascites, or pericardial effusion that requires drainage, and the researcher evaluates the symptoms to be stable after drainage, they can be enrolled;\n10. Occurrence of arterial\u002Fvenous thrombosis events within the first 6 months of enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n11. Known genetic or acquired bleeding and thrombophilia tendencies (such as in hemophilia patients, coagulation dysfunction, etc.);\n12. Within 6 months prior to the start of treatment, there has been an abdominal fistula, gastrointestinal perforation, or abdominal abscess;\n13. Significant vascular disease (such as aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) occurred within 6 months prior to the start of the study treatment;\n14. Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures;\n15. Received major surgical treatment (excluding diagnosis) within 4 weeks before the start of the study treatment or expected to undergo major surgical treatment during the study period;\n16. Urine routine shows that urine protein is ≥++and has been confirmed to have a 24-hour urine protein level\\>1.0 g;\n17. Previously received radiotherapy (excluding palliative radiotherapy for bone lesions), chemotherapy, surgery (excluding biopsy), and less than 4 weeks before the first study medication after completion of treatment (last medication); The last dose of antibody administration is less than 4 weeks after the first study medication; Molecular targeted therapy (including other oral targeted drugs used in clinical trials) for patients with less than 5 drug half lives from the first study drug, or adverse reactions caused by previous treatment (excluding hair loss) that have not recovered to ≤ CTCAE grade 1;\n18. Suffering from active infection, having unexplained fever ≥ 38.5 ℃ within 7 days before medication, or baseline white blood cell count\\>15 × 109\u002FL;\n19. Suffering from congenital or acquired immune dysfunction (such as HIV infected individuals); Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥ 2000 IU\u002Fml, or hepatitis C virus antibody positive;\n20. Previously received anti angiogenic therapy;\n21. According to the researchers' judgment, the patient may have other factors that may affect the research results or cause the study to be terminated midway, such as alcohol abuse, drug abuse, other serious illnesses (including mental illnesses) that require concomitant treatment, serious laboratory test abnormalities, and family or social factors that may affect the patient's safety.",{"count":178,"type":21},65,[180,181],"PHASE1","PHASE2","The efficacy and safety of Pazopanib combined with Palbociclib in the third line and above treatment of refractory solid tumors co amplified in the 11q13 region (FGF3\u002F4\u002F19\u002FCCND1).",[184,185,28],"Solid Tumor, Adult","Next-generation Sequencing","2025-03-25",{"date":188,"type":38},"2025-03-26",{"date":190,"type":38},"2024-11-27",{"date":192,"type":21},"2025-12-31",{"name":194,"class":45},"Tianjin Medical University Second Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":206,"studyType":23,"phases":4,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100575739","precision-therapy-based-on-immune-microenvironment-by-transcriptome-sequencing-of-osteosarcoma-a-prospective-multi-cohort-exploratory-clinical-study-100575739","NCT06776198","Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study","PTMTO","Inclusion Criteria:\n\n* (i) patients who have been suspected for osteosarcoma with enough clinical or radiographic information;\n* (ii) patients who have evaluable lesions to resect or follow;\n* (iii) patients who are planned to be operate with enough flesh specimens for this study.\n\nExclusion Criteria:\n\n* (i) clinical information was not complete;\n* (ii) lost to follow-up.","8 Years","70 Years",{"count":205,"type":21},100,"100 Years","Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers. They provided a visual tool revealing the TME subtypes integrated with targetable genomic alterations, which provided a planetary view of each tumor that can aid in oncology clinical decision making. We aim to use this tool to prospectively analyse the biopsy specimens of osteosarcomas to identify their TME subtypes so as to deliver appropriate treatment strategy if these osteosarcomas experience disease progression afterwards. We will compare the past sequencing date stored in PKUPH bank so as to compare the event-free survival(EFS) of these patients to check the Superiority of this method later.",[209,210,211,28],"Osteosarcoma","Transcriptome","Tumor Microenvironment",[213,214,215,99],"osteosarcoma","transcriptome","tumor microenviroment","2025-01-21",{"date":218,"type":38},"2025-01-24",{"date":220,"type":21},"2025-03-01",{"date":222,"type":21},"2027-06-01",{"name":224,"class":45},"Peking University People's Hospital",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":60,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":46},"100572909","phase-2-precision-medicine-trial-based-on-molecular-matching-therapy-for-patients-with-standard-treatment-exhaustion-100572909","NCT06739395","Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","A Pan-Cancer Basket, Real World, Open-label, Multicenter Study on Molecular Matching Therapy Guided by Molecular Tumor Boards (MTB) for Pan Solid Tumor Patients With Standard Treatment Exhaustion","Inclusion Criteria:\n\n1. Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology;\n2. ECOG score 0-4 (3-4 points only for patients with tumor burden);\n3. Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment;\n4. At least one measurable lesion that meets the RECIST 1.1 standard;\n5. Expected survival period ≥ 3 months;\n6. Age ≥ 18 years old;\n7. Tumor tissue blocks with sufficient formalin fixed paraffin embedding (FFPE), or chest or ascites with cancer cells detected during treatment (not less than 200ml), or excised metastatic lymph nodes, or peripheral blood (approximately 5m1) can be used for genetic testing;\n8. Understand and voluntarily participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients who have actively undergone or are currently participating in clinical trials for treatment;\n2. Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection, mental diseases\u002Fsocial conditions that limit the compliance with the research requirements) that the researchers think will confuse the research treatment response analysis;\n3. Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.",{"count":233,"type":21},300,[181],"The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.",[237,28],"Solid Tumor","2024-12-12",{"date":240,"type":38},"2024-12-18",{"date":242,"type":38},"2024-11-01",{"date":244,"type":21},"2027-05-01",{"name":194,"class":45}]